ABSTRACT Antiserum to a glycoprotein antigen complex of 23,000 and 30,000 dalton subunits (p23,30), isolated and purified from a human lymphoblastoid B cell line, was shown to be highly specific for human bursal-equivalent-processed (B) 
Insight into the cellular origin and differentiation pathways for a variety of lymphoid neoplasms has resulted from recent studies identifying normal lymphocyte differentiation antigens and receptors -on the surface of these neoplastic cells (1) (2) (3) (4) (5) . For example, it is well recognized now that the majority of cases of chronic lymphatic leukemia (CLL) and most of the lymphoblastic lymphomas bear surface immunoglobulin, Fc, and complement receptors, and thus point to a bursal-equivalent-processed (B) cell origin for these neoplasms. Moreover, recent studies published while the present paper was in preparation have indicated that a human Bcell-specific alloantigen is expressed on cells of approximately 80% of cases of acute lymphoblastic leukemia (ALL) (6) . In contrast, thymus-processed (T) lymphocyte receptor for sheep erythrocytes is present on blast cells from a minority of patients with ALL, and on the neoplastic cell associated with the Szezary syndrome (5, 7, 8) . However, since the Bcell-specific antigens are expressed on certain T lymphocytes and stimulated T cells, their presence on a subset of ALL cases does not clearly associate this subgroup with a B cell origin (9) .
Recently, a glycoprotein antigen complex of 23,000 and 30,000 dalton subunits (p23,30) was isolated and purified from a human lymphoblastoid B cell line and was used to prepare an antiserum (anti-p23,30) which has been shown to be highly specific for human B cells, but to be completely unreactive with both T cells and human T cell lymphoblastoid lines (10, 11) . Moreover immunoglobulin. This antibody (anti-p23,30) apparently recognizes a unique antigen on B lymphocytes that is probably the human counterpart of murine Ia antigens (12, 13) . In the present, study, the distribution of this antigen on a variety of other normal and leukemic human cells of both lymphoid and myeloid origin has been explored. Granulocytes, red cells, and phytohemagglutinin-induced T cell blasts were prepared by previously described techniques (15) . Single cell suspensions from normal human thymuses and fetal liver were prepared, Ficoll-Hypaque purified, and washed as above.
Preparation of Antisera. p23,30 antigen and rabbit antiserum to this antigen were described in a previous paper ( (15, 17, 18) . RESULTS 
Distribution of p23,30 antigen on normal human cells
The binding of rabbit anti-p23,30 antibody to the surface of various cell populations was investigated by indirect immunofluorescence on a the fluorescence-activated cell sorter utilizing fluoresceinated goat Fab2 absorbed with human Ig and specific for rabbit Fc as the developing reagent. Binding curves plotting fluorescence intensity versus cell number (40,000 cells counted) are shown with human peripheral lymphocytes in Fig. 1A . Approximately 20% of human peripheral lymphocytes bind p23,30 antibody. In 25 patients studied, the binding varied between 15 and 25% and was consistent with the complement-mediated lysis data (10) . Indirect fluorescent binding studies were then carried out with separated T, B, and Null cell populations (Table 1 ). All human B cells stained with p23,30 antibody strongly in dilutions of the antisera as great as 1/1000 (Fig. 1B) . In contrast, T cells did not stain with any of the dilutions of p23,30 antibody tested (Fig. IC) to or greater than that obtained with normal B cells (Fig. 2) . The reactivity of p23,30 antibody on acute lymphoblastic leukemic cells is illustrated in Fig. 3 (10, 11) .
Thus, the presence of this antigen on CLL cells defines yet another surface antigen relating this class of leukemic cells to normal B cells.
The finding that p23,30 antibody reacted strongly with cells from 21 of 24 patients with acute lymphoblastic leukemia was unanticipated in view of the widely held assumption that most childhood leukemias were either T cell or undifferentiated cell disorders. The intensity of staining with p23,30 antibody with acute lymphoblastic leukemic cells was equal to or greater than that found with the normal B cells. The three p23,30-negative cases, however, were totally unreactive even though they were cytologically indistinguishable from cells obtained from p23,30-positive patients. Moreover, both p23,30-positive and -negative cells were equally reactive with anti-ALS. Of greater importance was the observation that the p23,30-negative ALL patients were reactive with both anti-B.K. antisera (thymocyte specific) as well as with an anti-T cell serum (unpublished). In contrast, the p23,30-positive patients were completely unreactive with either of these sera. Thus, all acute lymphoblastic leukemic cells could be accounted for as either having B or T cell surface markers. Similar results were obtained by Fu et al. with still another set of reagents capable of reacting with B cells. Their results showed that the majority of CLL cells and acute lymphoblastic cells stained with these B cell alloantisera. On the other hand, T cells and sheep erythrocyte rosette-positive ALL cells were unreactive (6) . Their antibodies were thought to be directed at a human Ia antigen, and were capable of inhibiting mixed lymphocyte cultures (MLC). Similarly, anti-p23,30 antiserum is B-cell-specific, inhibits mixed lymphocyte cultures, and, perhaps of greater importance, p23,30 is structurally related to murine Ia antigens (10-13). In contrast, Greaves et al. showed that most ALL patients reacted with an antibody which was neither Tnor B-cell-specific (20) . How their leukemia-specific antigens are related to p23,30 or other B cell alloantisera remains to be defined. However, it is clear that as the heterogeneity of the. lymphoid system as defined by cellular probes -- 
